Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for DiaMedica Therapeutics, Inc. (DMAC : NSDQ)
 
 • Company Description   
DiaMedica Therapeutics Inc. is a biopharmaceutical company. It engages in the development of novel recombinant proteins and monoclonal antibodies. The companys lead product principally consists DM199, a recombinant human tissue kallikrein-1 protein. It operates primarily in the United States and Canada. DiaMedica Therapeutics Inc. is headquartered in Minneapolis, Minnesota.

Number of Employees: 28

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.76 Daily Weekly Monthly
20 Day Moving Average: 301,985 shares
Shares Outstanding: 42.88 (millions)
Market Capitalization: $161.24 (millions)
Beta: 1.17
52 Week High: $6.82
52 Week Low: $2.83
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -8.07% -13.05%
12 Week 7.12% -10.13%
Year To Date -30.75% -35.14%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
301 CARLSON PARKWAY SUITE 210
-
MINNEAPOLIS,MN 55305
USA
ph: 763-496-5454
fax: 763-710-4456
skellen@diamedica.com http://www.diamedica.com
 
 • General Corporate Information   
Officers
Rick Pauls - Chief Executive Officer; President and Director
James Parsons - Chairman
Scott Kellen - Chief Financial Officer and Secretary
Michael Giuffre - Director
Richard Kuntz - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 25253X207
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/06/25
Share - Related Items
Shares Outstanding: 42.88
Most Recent Split Date: 11.00 (0.05:1)
Beta: 1.17
Market Capitalization: $161.24 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.18 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.72 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/06/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 4.75
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -28.57%
vs. Previous Quarter: 0.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -61.35
12/31/24 - -51.85
ROA
06/30/25 - -
03/31/25 - -55.53
12/31/24 - -47.68
Current Ratio
06/30/25 - -
03/31/25 - 8.02
12/31/24 - 8.28
Quick Ratio
06/30/25 - -
03/31/25 - 8.02
12/31/24 - 8.28
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 0.79
12/31/24 - 0.95
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.03
12/31/24 - 0.03
 

Powered by Zacks Investment Research ©